Group 1 - The National Health Commission of China has issued notifications prohibiting the use of "ileal-jejunal anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease treatment [2][3] - The cervical deep lymphatic vessel/lymph node-venous anastomosis is primarily used for treating stubborn lymphedema, but its application for Alzheimer's disease lacks clear indications and contraindications, as well as high-quality evidence supporting its safety and efficacy [2] - The ileal-jejunal anastomosis, used for restoring intestinal continuity, has been deemed to lack foundational theoretical support and high-quality evidence for its safety and efficacy in treating type 2 diabetes [3] Group 2 - The domestic anastomosis device market may be impacted by these prohibitions, with the top 10 manufacturers in China including Johnson & Johnson, Covidien, Frankmann, Yisi Medical, Tianchen Medical, Palt Medical, David Medical, Rich Surgical, Yintukang Medical, and Brolansense [3] - Relevant listed companies in this sector include Dongxing Medical and Tianchen Medical, which may face challenges due to the new regulations [3]

Core Viewpoint - The National Health Commission has prohibited the use of jejunoileal anastomosis for the treatment of type 2 diabetes and cervical deep lymphatic/lymph node-venous anastomosis for Alzheimer's disease treatment due to safety and efficacy concerns [1][2] Group 1: Jejunoileal Anastomosis - The jejunoileal anastomosis is primarily used for intestinal obstruction, tumor resection reconstruction, or congenital deformity repair, but its application in diabetes treatment has been deemed unsafe and ineffective [1][2] - The procedure may lead to severe complications such as liver failure and malnutrition, and it has been eliminated from clinical use in the weight loss metabolic field due to high complication rates [2] Group 2: Cervical Deep Lymphatic/Lymph Node-Venous Anastomosis - The cervical deep lymphatic/lymph node-venous anastomosis lacks direct evidence from preclinical studies for its application in Alzheimer's disease treatment, and it is still in the early exploratory stage of clinical research [2] - Local health authorities are required to investigate the clinical application of this procedure and ensure that medical institutions immediately cease its use while enhancing regulatory oversight [2]

对于"颈深淋巴管/结—静脉吻合术"，国家卫健委发文指出，其近期获悉有个别医疗机构开 展"颈深淋巴管/结—静脉吻合术"治疗阿尔茨海默病，为进一步加强医疗技术临床应用管理， 国家卫健委组织专家对该技术进行评估，评估认为 该技术处于临床研究早期探索阶段，适应 证及禁忌证尚不明确，安全性、有效性缺乏高质量循证医学证据支撑 。 根据《医疗技术临床 应用管理办法》（国家卫生健康委员会令第1号）有关规定， 决定禁止将"颈深淋巴管/结— 静脉吻合术"应用于阿尔茨海默病治疗 。 7月8日，国家卫健委网站发布两则重要通知： 《关于禁止将"颈深淋巴管/结—静脉吻合 术"应用于阿尔茨海默病治疗的通知》《关于禁止将"空肠回肠吻合术"应用于2型糖尿病治疗 的通知》 。 国家卫健委官网截图 来源：央广网 地方各级卫生健康行政部门要督促辖区内医疗机构停止将"颈深淋巴管/结—静脉吻合术"应用 于阿尔茨海默病治疗，并做好有关患者的随访服务等工作。 同时，在该技术具备充分相关临 床前研究证据后，指导有条件的医疗机构加强临床研究设计，在伦理委员会充分论证的前提 下，科学、规范开展临床研究。国家卫健委将根据临床研究情况，适时对该技术临床应用再 次组织 ...

Group 1 - The "Difficult Children Medical Security Program" initiated by Suzhou Charity Federation and Ping An Health Insurance has provided urgent assistance to over 1,850 children and their families [1] - Since its launch in 2019, the program has covered 32,000 instances of difficult children, with a total compensation of 6.1137 million yuan [1] - The program will upgrade this year to include 10 new medical health services such as health doctors, scientific nutrition intervention, and post-hospital home care guidance [1] Group 2 - The "Sunshine Plan" for caring for disabled children's rehabilitation was launched in early last month, providing up to 1,000 yuan per person per month for children aged 7 to 14 with disabilities in specific districts [2] - Ping An Health Insurance Suzhou branch has invested 800,000 yuan in the "Sunshine Plan" project [2]

【东盟专线】东盟学子广西毕业：老挝女孩圆医学梦 印尼兄妹盼归国创业 中新社广西柳州6月28日电 题：东盟学子广西毕业：老挝女孩圆医学梦 印尼兄妹盼归国创业 作者 林馨 6月27日，留学生马丽文在毕业典礼上与从老挝前来的亲人合影留念。(受访者供图) 在广西科技大学27日举行的毕业典礼上，老挝留学生马丽文成为全场焦点：她的父母、兄弟等十位亲人 跨国而来，见证这一重要时刻。"当家人手捧鲜花向我走来，我紧紧拥抱住他们，感谢他们支持我的梦 想。"马丽文说。 2018年，怀揣着"成为一名救死扶伤的医生"这一理想，马丽文选择到中国学习。"中国的医疗技术和教 育水平非常先进，是理想的'取经'之地。"她坦言。 克服语言关，是马丽文来中国学习的首要任务。"我们班里只有我一名外国学生，中国学生都很热情， 帮助我尽快融入当地生活。"如今，马丽文早已能说一口流利的汉语。 对马丽文而言，在中国医院实习的经历尤为珍贵。她在急诊科、内科、外科轮转学习，逐步参与临床实 践。第一次站上手术台的紧张感，她仍记忆犹新："心跳得飞快，多亏带教老师指导我完成缝合、打结 等操作……" 同样怀抱梦想来中国求学的，还有来自印度尼西亚的兄妹林建全和林婉詠。两人 ...

金十数据6月12日讯，医疗技术公司Brainlab AG宣布计划在法兰克福证券交易所进行IPO，成为今年寻 求上市的最新一家德国公司。根据周四的一份声明，这家总部位于慕尼黑的公司计划在未来几周内在受 监管的市场上市。该公司表示，高达2亿欧元的增资将用于资助增长计划，加强资产负债表和销售团 队。此次发行还将包括二级股票，但公告没有说明发行数量。Brainlab开发的软件使手术和癌症治疗更 加精确、数据驱动和更少侵入性。它还帮助医院计划和指导医疗程序。 医疗技术公司Brainlab宣布法兰克福IPO计划 ...

英国财政大臣：将国家医疗服务体系（NHS）的技术预算增加50%。 ...

植入式给药装置或称完全植入式输液港（ TIAP ）（简称"输液港"）是一种长期留置于人体内的输液装置，一般由皮下植入式输液 港（以下简称"港体"）、导管两部分组成，部分产品带有独立的连接件。其中港体与连接件植入皮下，导管可植入静脉、动脉、腹 膜内或椎管内（鞘内 / 硬膜外）等部位，为患者建立长期液体通路，可经皮反复穿刺港体的注射座向人体内输注药物或抽吸体液， 适用于需要进行化疗、营养支持及其他临床需反复输注或抽吸的患者。 植入静脉输液港后只需每 4 周进行一次维护，最长使用期限可达数年，最大限度提升治疗安全性和患者生活质量，减少输液对病 人生活的干扰。 根据 QYResearch （恒州博智）的统计及预测， 2024 年全球植入式给药装置市场销售额达到了 5.65 亿美元，预计 2031 年将达到 6.92 亿美元，年复合增长率（ CAGR ）为 2.98 % （ 2025-2031 ）。 全球植入式给药装置市场的增长主要受到多方面因素推动。首先，癌症、糖尿病等慢性疾病患者数量的持续上升，使得长期静脉 输液需求增加，植入式输液港因其减少反复穿刺、降低血管损伤的优势，受到越来越多的患者和医生青睐。其次，医疗技术 ...

Core Viewpoint - Yantai Yuhuangding Hospital has successfully implemented a new electromagnetic navigation technology for nasoenteric tube placement, enhancing nutritional support for critically ill patients and marking a significant advancement in the hospital's enteral nutrition and nursing techniques [2][3][6] Group 1: Technology Implementation - The nursing team at Yantai Yuhuangding Hospital's East District has successfully performed nasoenteric tube placement using electromagnetic navigation technology, which opens new pathways for nutritional support in critically ill patients [2][6] - Traditional blind insertion techniques for nasoenteric tubes are time-consuming and heavily reliant on the experience of healthcare personnel, leading to challenges in ensuring successful placement [2][3] Group 2: Patient Case Study - A 67-year-old female patient with multiple severe conditions required enteral feeding and faced challenges due to her deep sedation and slow gastrointestinal motility, resulting in failed attempts at blind insertion [2][3] - The electromagnetic navigation-guided procedure was completed in just 20 minutes without causing any discomfort to the patient, ensuring the continuation of prone ventilation and avoiding interruptions in nutrition [3][6] Group 3: Advantages of New Technology - The electromagnetic navigation system acts like a precise navigator, allowing for accurate placement of the nasoenteric tube while monitoring its trajectory and real-time position, significantly improving success rates and reducing placement time compared to traditional methods [6] - This new technique is non-invasive and radiation-free, providing real-time alerts for any abnormal resistance or deviation during the procedure, thereby minimizing complications and enhancing patient comfort [6] Group 4: Future Implications - The successful application of this technology reflects the hospital's commitment to exploring and innovating medical techniques, with the potential for broader implementation to improve healthcare services for critically ill patients [6]

Core Insights - The collaboration between Carl Zeiss and He Eye Hospital marks the introduction of advanced refractive surgery technology in Northeast China, providing a revolutionary "10-second rapid vision correction" experience for myopic patients [1][3] - The new generation of all-laser technology, VISUMAX 800 and SMILE pro, offers significant improvements in surgical efficiency, precision, and safety, enhancing patient comfort during procedures [1][2] Group 1: Technology and Innovation - The VISUMAX 800 technology reduces single-eye scanning time from 23 seconds to under 10 seconds, improving efficiency by 36% and minimizing patient discomfort during surgery [1] - The technology features CentraLign intelligent navigation and OcuLign eye rotation compensation systems, which track eye movements in real-time and reduce postoperative residual astigmatism [1] - The dual robotic arm design ensures stable and reliable operation during surgery, enhancing overall safety [1] Group 2: Clinical Application and Experience - He Eye Hospital successfully completed its first SMILE pro surgery on May 15, with the first patient expressing high satisfaction with the quick and nearly painless procedure [2] - The hospital has established a comprehensive service management system, ensuring standardized operations and clinical experience to support the application of this breakthrough technology [2] - He Eye Hospital has been recognized as one of the first high-end refractive surgery institutions in China, emphasizing its commitment to technological innovation and patient-centered care [2] Group 3: Financial Services and Accessibility - The launch of the "Bright Future" financial service plan in collaboration with Industrial Bank provides low-interest installment credit services to myopic patients, making advanced technology more accessible [2]